Strain Name:

B10.D2-Tg(C3-1-TAg)cJeg/J

Stock Number:

003382

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
GenerationN9p
 
Donating Investigator Jeff Green,   NIH

Appearance
black
Related Genotype: a/a

Description
This transgenic strain is a model for the study of multistage oncogenesis in the prostate and mammary glands. Male transgenic mice develop prostatic hyperplasia in early life that progresses to adenoma or adenocarcinoma in about half of the animals which survive longer 7 months of age. Female animals generally develop mammary intraepithelial neoplasia with similarities to DCIS by 3 months of age with subsequent development of mammary adenocarcinoma by 6 months of age in 100% of the animals. About 10 - 15% of female mice develop lung metastases, although lung metastases from prostate cancer is extremely rare. Bone metastases have not been observed. Please note that the phenotype description above was developed for this allele on an FVB background (stock number 3381). The mammary and prostate tumor phenotypes may be different on the C57BL/10 background in this strain.

Control Information

  Control
   Noncarrier
   000461 B10.D2-Hc0 H2d H2-T18c/oSnJ
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(C3-1-TAg)cJeg allele
003380   B6.FVB-Tg(C3-1-TAg)cJeg/J
003381   FVB-Tg(C3-1-TAg)cJeg/J
View Strains carrying   Tg(C3-1-TAg)cJeg     (2 strains)

View Strains carrying other alleles of TAg     (13 strains)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Tg(C3-1-TAg)cJeg/0

        involves: FVB/N
  • tumorigenesis
  • increased tumor incidence (MGI Ref ID J:46513)
    • some mice exhibit mixed tumors of the sweat glands and occasional nasal proliferative or neoplastic lesions develop from the nasal turbinate epithelium unlike in wild-type mice
    • adenocarcinoma (MGI Ref ID J:46513)
      • at 7 months, 10% to 20% male mice develop adenocarcinomas of the urethral and bulbourethral glands unlike in wild-type mice
      • mammary adenocarcinoma (MGI Ref ID J:52786)
        • by 6 months of age female mice develop multiple mammary ductular adenocarcinomas unlike in wild-type mice
        • at 6 months, 10% of female mice exhibit lung metastasis
        • adenocarcinoma cells exhibit increased rates of apoptosis compared to cells in wild-type mice
      • prostate adenocarcinoma (MGI Ref ID J:72324)
        • at 7 months of age, 19% of mice exhibit carcinomas in the ventral lobe and 3% in the dorsolateral lobe unlike in wild-type mice
        • after 8 months, 40% of mice exhibit carcinomas in the ventral lobe and 13% in the dorsolateral lobe unlike in wild-type mice
        • the number of apoptotic cells in the prostate is greater than in wild-type mice
        • at 7 months in the ventral prostate and 11 months in the dorsolateral prostate
        • however, no metastasis is observed
    • prostate intraepithelial neoplasia (MGI Ref ID J:72324)
      • at 5 to 6 months, mice develop low to high grade prostate intraepithelial neoplasia (PIN) unlike wild-type mice
      • low-grade PIN is observed in 83% and 100% of the ventral prostate at 2 to 3 months and 4 to 12 months, respectively, unlike wild-type mice
      • at 5 months, ventral and dorsolateral lobes exhibit high grade PIN unlike in wild-type mice
      • high-grade PIN is observed on 88% and 100% of mice at 5 to 8 months and more than 8 months, respectively, unlike in wild-type mice
      • numbers of PIN lesions increase with age in the ventral and dorsolateral lobes unlike wild-type mice
      • the number of apoptotic cells in the prostate is greater than in wild-type mice
      • at 2 to 3 months, low-grade prostate intraepithelial neoplasia (PIN) is observed in the ventral and dorsolateral prostates unlike in wild-type mice
      • at 5 months, high-grade PIN is observed in both lobes unlike in wild-type mice
      • PIN lesions increase with age
  • endocrine/exocrine gland phenotype
  • abnormal prostate physiology (MGI Ref ID J:46513)
    • prostate cells exhibit increased proliferation and apoptosis rates compared to in wild-type mice according to their degree of prostate intraepithelial neoplasia
  • mammary gland hyperplasia (MGI Ref ID J:46513)
    • at 2 months of age, female mice exhibit atypical ductal hyperplasias unlike in wild-type mice
    • hyperplastic cells exhibit increased rates of apoptosis compared to cells in wild-type mice
  • reproductive system phenotype
  • abnormal prostate physiology (MGI Ref ID J:46513)
    • prostate cells exhibit increased proliferation and apoptosis rates compared to in wild-type mice according to their degree of prostate intraepithelial neoplasia
  • mammary gland hyperplasia (MGI Ref ID J:46513)
    • at 2 months of age, female mice exhibit atypical ductal hyperplasias unlike in wild-type mice
    • hyperplastic cells exhibit increased rates of apoptosis compared to cells in wild-type mice
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Increased Tumor Incidence
      Mammary Gland Tumors
      Prostate Tumors

Reproductive Biology Research
Gonadal Tumors
Prostate Tumors
      Tetop Tet System

TAg related

Apoptosis Research
Extracellular Modulators

Genes & Alleles

Gene & Allele Information

 
Allele Symbol Tg(C3-1-TAg)cJeg
Allele Name transgene insertion C, Jeffrey E Green
Allele Type Transgenic (random, expressed)
Common Name(s) C3(1)-SV40 T antigen; C3(1)/SV40; C3(1)/SV40T; C3(1)/T antigen (Tag); C3(1)/T(AG); C3(1)/TAg; Large T;
Mutation Made By Jeff Green,   NIH
Strain of OriginFVB/N
Expressed Gene TAg, SV40 large T-antigen, SV40
Simian virus 40 T antigen (SV40Tag) is a multifunctional regulatory protein that stimulates gene transcription and forms complexes with cell cycle-regulatory proteins such as Trp53 and Rb1 that are implicated in human breast cancer.
Promoter C3(1), C3(1), rat
Molecular Note This transgene contains the rat prostatic binding protein C3 promoter (Pbpc3) and the wild-type allele of the SV40 large tumor antigen (TAg) gene. Founder c carried 6 copies of the transgene. Founders f, g, i, j, k, and l were also generated. Two transgenic lines (c and l) were produced. [MGI Ref ID J:52786]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

TAg, SV, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References

Selected Reference(s)

Maroulakou IG; Anver M; Garrett L; Green JE. 1994. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 91(23):11236-40. [PubMed: 7972041]  [MGI Ref ID J:52786]

Additional References

Jorcyk CL; Liu ML; Shibata MA; Maroulakou IG; Komschlies KL; McPhaul MJ ; Resau JH ; Green JE. 1998. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate 34(1):10-22. [PubMed: 9428383]  [MGI Ref ID J:45372]

Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE. 1997. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice. Mol Carcinog 20(2):168-74. [PubMed: 9364206]  [MGI Ref ID J:72307]

Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE. 1996. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56(13):2998-3003. [PubMed: 8674054]  [MGI Ref ID J:72136]

Shibata MA; Ward JM; Devor DE; Liu ML; Green JE. 1996. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21):4894-903. [PubMed: 8895741]  [MGI Ref ID J:72324]

Tg(C3-1-TAg)cJeg related

Calvo A; Feldman AL; Libutti SK; Green JE. 2002. Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice. Cancer Res 62(14):3934-8. [PubMed: 12124322]  [MGI Ref ID J:77958]

Calvo A; Yokoyama Y; Smith LE; Ali I; Shih SC; Feldman AL; Libutti SK; Sundaram R; Green JE. 2002. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 101(3):224-34. [PubMed: 12209972]  [MGI Ref ID J:78871]

Cardiff RD; Anver MR; Gusterson BA; Hennighausen L; Jensen RA; Merino MJ; Rehm S; Russo J; Tavassoli FA; Wakefield LM; Ward JM; Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments] Oncogene 19(8):968-88. [PubMed: 10713680]  [MGI Ref ID J:61035]

Cha TL; Qiu L; Chen CT; Wen Y; Hung MC. 2005. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65(6):2287-95. [PubMed: 15781642]  [MGI Ref ID J:97163]

Diwadkar-Navsariwala V; Prins GS; Swanson SM; Birch LA; Ray VH; Hedayat S; Lantvit DL; Diamond AM. 2006. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A 103(21):8179-84. [PubMed: 16690748]  [MGI Ref ID J:110207]

Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R. 2001. 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice. Cancer Res 61(20):7449-55. [PubMed: 11606379]  [MGI Ref ID J:72279]

Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C. 2000. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19(8):1020-7. [PubMed: 10713685]  [MGI Ref ID J:61011]

Gupta V; Carey JL; Kawakubo H; Muzikansky A; Green JE; Donahoe PK; MacLaughlin DT; Maheswaran S. 2005. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A 102(9):3219-24. [PubMed: 15728372]  [MGI Ref ID J:97014]

Huh JI; Calvo A; Charles R; Green JE. 2006. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression. Cancer Res 66(7):3495-503. [PubMed: 16585173]  [MGI Ref ID J:108216]

Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE. 2005. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24(5):790-800. [PubMed: 15592523]  [MGI Ref ID J:96009]

Jorcyk CL; Liu ML; Shibata MA; Maroulakou IG; Komschlies KL; McPhaul MJ ; Resau JH ; Green JE. 1998. Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. Prostate 34(1):10-22. [PubMed: 9428383]  [MGI Ref ID J:45372]

Kavanaugh C; Green JE. 2003. The use of genetically altered mice for breast cancer prevention studies. J Nutr 133(7 Suppl):2404S-2409S. [PubMed: 12840216]  [MGI Ref ID J:85028]

Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141-52. [PubMed: 18242514]  [MGI Ref ID J:131913]

Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE. 2001. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. Oncogene 20(16):2044-9. [PubMed: 11360188]  [MGI Ref ID J:69250]

Liu ML; Von Lintig FC; Liyanage M; Shibata MA; Jorcyk CL; Ried T; Boss GR; Green JE. 1998. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17(18):2403-11. [PubMed: 9811472]  [MGI Ref ID J:50935]

Liu R; Varghese S; Rabkin SD. 2005. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 65(4):1532-40. [PubMed: 15735042]  [MGI Ref ID J:97030]

Maroulakou IG; Shibata MA; Anver M; Jorcyk CL; Liu Ml; Roche N; Roberts AB; Tsarfaty I; Reseau J; Ward J; Green JE. 1999. Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression. Oncogene 18(39):5435-47. [PubMed: 10498897]  [MGI Ref ID J:57996]

Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE. 1997. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice. Mol Carcinog 20(2):168-74. [PubMed: 9364206]  [MGI Ref ID J:72307]

Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE. 2004. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 74(11):1345-57. [PubMed: 14706566]  [MGI Ref ID J:88119]

Mustafa A; Kruger WD. 2008. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 14(15):4935-42. [PubMed: 18676768]  [MGI Ref ID J:142161]

Nunez NP; Oh WJ; Rozenberg J; Perella C; Anver M; Barrett JC; Perkins SN; Berrigan D; Moitra J; Varticovski L; Hursting SD; Vinson C. 2006. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 66(10):5469-76. [PubMed: 16707476]  [MGI Ref ID J:109048]

Oakes SR; Robertson FG; Kench JG; Gardiner-Garden M; Wand MP; Green JE; Ormandy CJ. 2007. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 26(4):543-53. [PubMed: 16862169]  [MGI Ref ID J:117839]

Shen Q; Brown PH. 2005. Transgenic mouse models for the prevention of breast cancer. Mutat Res 576(1-2):93-110. [PubMed: 15888345]  [MGI Ref ID J:100623]

Shibata MA; Jorcyk CL; Devor DE; Yoshidome K; Rulong S; Resau J; Roche N; Roberts AB; Ward JM; Green JE. 1998. Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen. Carcinogenesis 19(1):195-205. [PubMed: 9472712]  [MGI Ref ID J:45643]

Shibata MA; Jorcyk CL; Liu ML; Yoshidome K; Gold LG; Green JE. 1998. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol 26(1):177-82. [PubMed: 9502400]  [MGI Ref ID J:46513]

Shibata MA; Kavanaugh C; Shibata E; Abe H; Nguyen P; Otsuki Y; Trepel JB; Green JE. 2003. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24(3):453-9. [PubMed: 12663504]  [MGI Ref ID J:82837]

Shibata MA; Liu ML; Knudson MC; Shibata E; Yoshidome K; Bandey T ; Korsmeyer SJ ; Green JE. 1999. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18(10):2692-701. [PubMed: 10329616]  [MGI Ref ID J:55778]

Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE. 1996. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 56(13):2998-3003. [PubMed: 8674054]  [MGI Ref ID J:72136]

Shibata MA; Ward JM; Devor DE; Liu ML; Green JE. 1996. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 56(21):4894-903. [PubMed: 8895741]  [MGI Ref ID J:72324]

Shibata MA; Yoshidome K; Shibata E; Jorcyk CL; Green JE. 2001. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8(1):23-35. [PubMed: 11219490]  [MGI Ref ID J:67442]

Verschoyle RD; Edwards R; Nolan B; Greaves P. 2004. Articular Chondromatosis and Chrondroid Metaplasia in Transgenic TAg Mice. Toxicol Pathol 32(1):22-5. [PubMed: 14713544]  [MGI Ref ID J:88112]

Wang Z; Prins GS; Coschigano KT; Kopchick JJ; Green JE; Ray VH; Hedayat S; Christov KT; Unterman TG; Swanson SM. 2005. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146(12):5188-96. [PubMed: 16141391]  [MGI Ref ID J:104208]

Wigginton JM; Park JW; Gruys ME; Young HA; Jorcyk CL; Back TC; Brunda MJ; Strieter RM; Ward J; Green JE; Wiltrout RH. 2001. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166(2):1156-68. [PubMed: 11145697]  [MGI Ref ID J:66851]

Wild R; Yokoyama Y; Dings RP; Ramakrishnan S. 2004. VEGF-DT385 Toxin Conjugate Inhibits Mammary Adenocarcinoma Development in a Transgenic Mouse Model of Spontaneous Tumorigenesis. Breast Cancer Res Treat 85(2):161-71. [PubMed: 15111774]  [MGI Ref ID J:90175]

Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH. 2002. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11(5):467-74. [PubMed: 12010861]  [MGI Ref ID J:77199]

Wu K; Kim HT; Rodriquez JL; Munoz-Medellin D; Mohsin SK; Hilsenbeck SG; Lamph WW; Gottardis MM; Shirley MA; Kuhn JG; Green JE; Brown PH. 2000. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice Clin Cancer Res 6(9):3696-704. [PubMed: 10999763]  [MGI Ref ID J:64491]

Wu Y; Cui K; Miyoshi K; Hennighausen L; Green JE; Setser J; LeRoith D; Yakar S. 2003. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63(15):4384-8. [PubMed: 12907608]  [MGI Ref ID J:84849]

Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE. 2000. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res 60(24):6901-10. [PubMed: 11156389]  [MGI Ref ID J:66915]

Zhang X; Mehta RG; Lantvit DD; Coschigano KT; Kopchick JJ; Green JE; Hedayat S; Christov KT; Ray VH; Unterman TG; Swanson SM. 2007. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28(1):143-50. [PubMed: 16916863]  [MGI Ref ID J:116587]

Health & husbandry

Health & Colony Maintenance Information

Colony Maintenance

Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Price (US dollars $)
Cryorecovery Fee $1900.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Additional Supply Details

Pricing for International shipping destinations View USA Canada and Mexico pricing
Price (US dollars $)
Cryorecovery Fee $2470.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Additional Supply Details

Supply Details

Standard SupplyCryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.
Supply Notes
  • Cryorecovery - Standard.
    We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

  • This strain is included in the Induced Mutant Resource Colony collection.
  • Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

  Control
   Noncarrier
   000461 B10.D2-Hc0 H2d H2-T18c/oSnJ
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(3.12)